Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.21 and traded as low as $0.19. Northwest Biotherapeutics shares last traded at $0.1918, with a volume of 2,283,691 shares traded.
Northwest Biotherapeutics Stock Down 1.3%
The firm has a market cap of $321.18 million, a PE ratio of -0.01 and a beta of -0.67. The company’s 50 day moving average price is $0.21 and its two-hundred day moving average price is $0.23.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Recommended Stories
- Five stocks we like better than Northwest Biotherapeutics
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
